This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection.
1. Esophageal cancer patients who are pathologically confirmed as pT1a-MM stage or pT1b stage after endoscopic submucosal dissection； 2. No definite contraindications for chemo-radiotherapy； 3. Informed consent has been signed； 4. Refused surgery after endoscopic submucosal dissection.
1. Severe heart, brain, lung disease or renal dysfunction; 2. Previous history of other malignancies; 3. Prior radiation or chemotherapy 4. Researchers consider it inappropriate to participate in this experiment
Esophageal cancer patients, and pathologic-comfirmed pT1a-MM stage or pT1b stage
Cohort
Prospective
chemo-radiation
Radiationdifferent Chemo-radiotherapy regimen
Incidence of toxic events
esophageal stenosis, radiation pneumonitis, etc
3-year overall survival
the time from randomization until death from any cause
3-year local-regional recurrence free survival
the time from randomization until local-regional recurrence
Click on the lead sponsor to view all of their trials.
